{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:46:25Z","timestamp":1782906385431,"version":"3.54.5"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Venous thromboembolism (VTE) is a well\u2010known complication in adults receiving asparaginase (ASNase)\u2010based intensification chemotherapy for acute lymphoblastic leukaemia (ALL). The optimal preventative strategy is unclear. Our objective is to determine the effects of low\u2010molecular\u2010weight heparin (LMWH) as primary VTE prophylaxis. A single\u2010centred retrospective cohort study of adult patients with Philadelphia chromosome negative (Ph\u2212) ALL who received ASNase\u2010based intensification from 2001 to 2017, with prophylaxis given from 2011 to 2017. In all, 214 patients were included in this study with 99 in the historical control group and 125 in the prophylaxis group. The mean (range) enoxaparin dose was 0\u00b779\u00a0(0\u00b739\u20131\u00b72)\u00a0mg\/kg. Of the 125 patients in the prophylaxis group 17 (13\u00b76%) developed VTE during the intensification phase, while 27\/99 patients (27\u00b73%) in the control cohort experienced at least one thrombotic event (odds ratio [OR] 0\u00b742, 95% confidence interval [CI] 0\u00b721\u20130\u00b783). Overall, the main sites of VTE incidences included deep vein thrombosis in the lower extremity (54\u00b76%), pulmonary embolism (13\u00b76%) and catheter\u2010related thrombosis (22\u00b77%). In addition, we found that after adjusting for age, T\u2010phenotype ALL was associated with VTE development (OR 3\u00b707, 95% CI 1\u00b704\u20139\u00b708). There was no documented major bleeding in the prophylaxis group. LMWH prophylaxis reduced the incidence of symptomatic VTE in adult patients with ALL receiving intensification chemotherapy with ASNase.<\/jats:p>","DOI":"10.1111\/bjh.16695","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T12:55:21Z","timestamp":1589288121000},"page":"748-754","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase\u2010based therapy"],"prefix":"10.1111","volume":"191","author":[{"given":"Hassan","family":"Sibai","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1008-4194","authenticated-orcid":false,"given":"Ruiqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Biostatistics Princess Margaret Cancer Centre University Health Network Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Falcone","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Schimmer","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Schuh","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9251-3609","authenticated-orcid":false,"given":"Arjun","family":"Law","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"McNamara","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Maze","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yee","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Minden","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Chan","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Murphy","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Department of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Princess Margaret Cancer Centre University Health Network Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Brandwein","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Alberta Edmonton AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack T.","family":"Seki","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University Health Network Toronto ON Canada"},{"name":"Leslie Dan Faculty of Pharmacy University of Toronto Toronto ON Canada"},{"name":"Department of Pharmacy Princess Margaret Cancer Centre University Health Network Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.290"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-04-0372"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000356"},{"key":"e_1_2_7_5_1","first-page":"1","article-title":"Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management","author":"Bade NA","year":"2019","journal-title":"J Oncol Pharm Practice"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015511"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08524.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-017-1597-7"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07712.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.23.3077"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12561"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.596963"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.02.015"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(16)30130-X"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22146"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.02.003"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16695","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:02:32Z","timestamp":1693310552000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/bjh.16695"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16695","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"2020-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}